Clinical Trials Logo

Nosebleeds clinical trials

View clinical trials related to Nosebleeds.

Filter by:
  • None
  • Page 1

NCT ID: NCT05269849 Recruiting - Epistaxis Clinical Trials

Sirolimus for Nosebleeds in HHT

Start date: March 16, 2022
Phase: Phase 2
Study type: Interventional

This pilot study is to determine the safety and efficacy of oral sirolimus (blood trough level 6-10ng/ml) in patients with HHT that are experiencing moderate or severe epistaxis. The effect of oral sirolimus on epistaxis will be compared to baseline using the Patient-Reported Outcome of cumulative weekly nose Bleeding Duration (PRO-CB). The PRO-CB association with biomarker variability over the duration of the study will be investigated. In the pilot study subjects will be treated with 2mg of sirolimus once daily to obtain a trough level of 6-10ng/ml for 3 months.

NCT ID: NCT01406639 Withdrawn - Clinical trials for Hereditary Hemorrhagic Telangiectasia (HHT)

Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Start date: July 2011
Phase: Phase 1
Study type: Interventional

This study is for patients with recurrent epistaxis (nosebleeds) as a result of Hereditary Hemorrhagic Telangiectasia (HHT). The aim is to determine if ranibizumab, topically applied will diminish epistaxis in patients with HHT as measured by the HHT Epistaxis Severity Score (ESS), hematocrit, and hemoglobin and serum ferritin levels.